Sensitivity of the ViroSeq HIV-1 Genotyping System for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D

Journal of Molecular Diagnostics

Volumn 8, Issue 4, 2006, Pages 430-432

  Church, Jessica D ^a   Jones, Dana ^a   Flys, Tamara ^a   Hoover, Donald ^b   Marlowe, Natalia ^c   Chen, Shu ^d   Shi, Chanjuan ^a   Eshleman, James R ^a   Guay, Laura A ^a   Jackson, Brooks ^a   Kumwenda, Newton ^d   Taha, Taha E ^d   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c CELERA   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE;

AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; VIRUS GENE; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33746768966     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2006.050148     Document Type: Article

References (12)

1. Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J: Sensitivity and specificity of the ViroSeq HIV-1 Genotyping System for detection of HIV-1 drug resistance mutations using an ABI PRISM 3100 Genetic Analyzer. J Clin Micro 2005, 43:813-817
2. Halvas E, Aldrovandi G, Balfe JP, Beck IA, Boltz V, Frenkel LM, Hazelwood J, Johnson V, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley D, Nowicki M, Ziermann R, Zhao Y, Jennings C, Bremer J, Brambilla D, Mellors J: Updated, blinded, multicenter comparison of the sensitivity of different technologies to detect and quantify a minor drug-resistant HIV-1 variant. Antiviral Therapy 2003, 8:S102
3. Eshleman SH, Guay LA, Mwatha A, Brown E, Cunningham SP, Musoke P, Mmiro F, Jackson JB: Characterization of nevirapine (NVP) resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose NVP (HIVNET 012). J Acquir Immune Defic Syndr 2004, 35:126-130
4. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005, 192:30-36
5. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J. Bakaki P, Ducar C. Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 1999, 354:795-802
6. Jackson JB, Musoke P, Fleming T, Guay L, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet 2003, 362:859-868
7. Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, Nour S, Chen S, Liomba G, Miotti PG, Broadhead RL: Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004, 292:202-209
8. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR: LigAmp: sensitive detection of single nucleotide differences. Nat Methods 2004, 1:141-147
9. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH: Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after single dose NVP: HIVNET 012. J Infect Dis 2005, 192:24-29
10. Eshleman SH, Hackett J, Swanson P, Cunningham SP, Drews B, Brennan C, Devare SG, Zekeng L, Kaptué L, Marlowe N: Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System v2.0 for sequence-based analysis of diverse HIV-1 strains. J Clin Micro 2004, 42:2711-2717
11. Huang D, Eshleman SH, Brambilla DJ, Palumbo PE, Bremer JW: Evaluation of the editing process in HIV-1 genotyping assays. J Clin Micro 2003, 35:614-622
12. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, Heneine W: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005, 192:16-23